Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 8/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 6/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.44 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25087396 | 0.76 | F12 (0.47) | — | |
| SCHEMBL16480283 | 0.74 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT6SIRT5 | |
| SCHEMBL19473957 | 0.73 | SIRT2 (0.49) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL19474012 | 0.71 | MC4R (0.45) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL19473950 | 0.71 | MC4R (0.61) | FURIN | |
| SCHEMBL18717178 | 0.71 | SIRT2 (0.47) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL19473857 | 0.70 | MC4R (0.58) | FURIN | |
| SCHEMBL19473818 | 0.70 | FCGRT (0.50) | FURIN | |
| SCHEMBL22834029 | 0.69 | HPN (0.56) | SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL22834028 | 0.69 | HPN (0.56) | SIRT2SIRT1SIRT3FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063420-A1 | LONG ACTING GLUCAGON LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND METHODS OF USE | I2O THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063420-A1 | LONG ACTING GLUCAGON LIKE POLYPEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GCGR | SIRT2 177/4885SIRT1 148/4885SIRT3 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.